Loke C, Mollee P, McPherson I, et al. - This study was undertaken to ascertain the health outcomes of bortezomib in the ‘real world’ transplant‐ineligible elderly patients, compared to trial data. Researchers extracted patient and treatment data from an oncology information system, laboratory information system, and medical chart audits for three Queensland public hospitals. Seventy-four patients were distinguished; the median age was 75 years. The cohort consisted of 47% patients who were International Staging System stage III, 45% at stage II, and 8% at stage I. Researchers recruited individuals who had comorbidities, such as cardiac disease (41%), pulmonary disease (14%), diabetes (22%), peripheral neuropathy (14%) and other comorbidities (41%) at baseline. The individuals were older, had worse disease characteristics, and more comorbidities than individuals in the VISTA trial. It was shown that survival outcomes appeared worse, while response rates were similar. In the elderly population, bortezomib‐based treatment in the real world setting still carries a high risk of toxicity.